Skip to content
Breaking News

Breaking News

  • Home
  • World
  • Business
  • Health
  • Entertainment
  • Life Style
  • Sports
  • Toggle search form

Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro

Posted on April 24, 2025 By Admin No Comments on Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro


An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Brendan McDermid | Reuters

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant’s weight loss drug Zepbound and its diabetes treatment Mounjaro, the company’s latest attempt to crack down on the booming industry of copycat drugs.

In lawsuits filed Wednesday, Lilly accuses the sites — Mochi Health, Fella Health, Willow Health and Henry Meds — of deceiving consumers about “untested, unapproved drugs” and turning them away from Lilly’s medicines.

Lilly alleges the companies are claiming to offer personalized options when they are actually mass-marketing slightly different versions of Lilly’s drugs in order to skirt FDA rules. Lilly also claims some of the sites are selling formulations of the drugs that haven’t been studied, such as oral tablets and drops.

Fella, Willow and Henry Meds didn’t immediately respond to CNBC’s requests for comment. Mochi Health in a statement said its model “remains compliant with FDA guidance and pharmacy regulations.”

Lilly’s diabetes drug Mounjaro went into short supply in late 2022, allowing pharmacies and outsourcing facilities to produce the treatment, a practice called compounding. Novo Nordisk’s weight loss drug Wegovy was also in short supply, opening up the market for compounding GLP-1s.

That business boomed online, where people sought versions of the treatments if they couldn’t find the brand names or couldn’t get them covered by insurance. Mass compounding of tirzepatide, the active ingredient in Mounjaro and Zepbound, was supposed to stop last month after the Food and Drug Administration declared the shortage of the drugs over.

Some pharmacies kept doing it anyway, producing versions that differ slightly from the brand name, which could possibly keep them out of the FDA’s crosshairs. Earlier this month, Lilly sued two pharmacies, alleging they falsely marketed their products as personalized versions of the drugs that have been clinically tested and are made using stringent safety standards.

One of the telehealth platforms Lilly is now suing, Mochi Health, planned to continue selling compounded versions of tirzepatide, betting that offering personalized treatments would keep it out of legal trouble, Mochi CEO Myra Ahmad told CNBC in March.

Asked whether she feared legal action from Lilly, Ahmad said she wasn’t worried about her prescribers since “they have established patient-physician relationships” and “the beauty of medicine is really that they get full autonomy to decide what is the best way to manage their patients.”

Lilly in its filing Wednesday claimed Ahmad is not a licensed physician and that Mochi and its “unlicensed owners exercise undue influence and control over, among other things, the prescribing decisions of physicians” and as a result engage in the “unlawful corporate practice of medicine.”

Ahmad in a statement said the use of compounded medications “remains appropriate and legal when tailored to individual patient needs and prescribed by a licensed medical provider” and that Mochi’s physicians choose which treatments are best for their patients. She said she holds a doctor of medicine degree but is not practicing as CEO of Mochi.

Lilly makes a similar allegation against Fella Health, accusing the company of making “sweeping corporate decisions that dictate patient care, such as when Fella changed patients en masse from one tirzepatide formulation to another with additives.”

In all four cases, Lilly is seeking to stop the sites from marketing or selling tirzepatide. But it could take months, or even longer, for the cases to make their way through the courts.



Source link

Health Tags:Biotech and Pharmaceuticals, Business, business news, Health care industry, LILLY DRN

Post navigation

Previous Post: FDA stops sale of generic versions of Ozempic and Wegovy: What it means for patients
Next Post: Super Bowl champion Mekhi Becton’s mother seeks kidney transplant

More Related Articles

Beyond choice | The Express Tribune Health
Caroline Kennedy Calls RFK Jr. a ‘Predator’ in Letter to Senators Health
What are we controlling? | The Express Tribune Health
Yogurt & Honey: 2 key ingredients in your DIY facial – SUCH TV Health
Dispute involving Affordable Care Act’s preventive care coverage faces Supreme Court Health
China reports no ‘unusual or novel pathogens’ after WHO seeks data on respiratory illness outbreak Health

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Can A Vegan Diet Boost Sperm Health? Fertility Expert Wants You To Know THIS
  • Jeff Bezos and Lauren Sánchez’s wedding invite slammed over ‘ugly’ design
  • Paige Spiranac adds new chapter in ‘case study’ about her golf game
  • From NPS To UPS: Last Date To Opt For Unified Pension Scheme Extended By 3 Months Till September 30
  • Salman Khan reveals struggle with AVM and brain aneurysm on Kapil Sharma Show: Know what AVM is, its causes, and why it’s so serious | – Times of India

Categories

  • Business
  • Entertainment
  • Health
  • Life Style
  • Sports
  • World

Copyright © 2025 Breaking News.

Powered by PressBook Blog WordPress theme